

28 INTRODUCTION

29 It is widely accepted that most vulvar squamous cell carcinomas (VSCC)
30 originate from intraepithelial lesions that precede the development of VSCC by
31 a variable period of time ¹⁻³. Each type of VSCC, i.e., human papillomavirus
32 (HPV)-associated and HPV-independent, not only has particular histologic
33 features but is also associated with a distinct type of intraepithelial lesion ³.
34 Thus, HPV-associated VSCCs are usually of basaloid, warty or non-keratinizing
35 subtype and arise from high-grade intraepithelial lesions, also referred to as
36 vulvar intraepithelial neoplasia of usual type (HSIL/uVIN), which have basaloid
37 or warty features. In contrast, HPV-independent VSCCs, which are usually of a
38 keratinizing subtype, derive from a premalignant lesion named differentiated
39 vulvar intraepithelial neoplasia (dVIN) and are frequently associated with
40 chronic inflammatory lesions, especially lichen sclerosus (LS) ^{1,2}. However, this
41 correlation between histological features and HPV involvement is not always the
42 rule, and there is increasing evidence of a frequent overlap between HPV status
43 and the histological characteristics of VSCC ³⁻⁶. Thus, the presence of
44 keratinizing, basaloid, warty features or koilocytotic changes is highly unreliable
45 to classify the tumor as HPV-associated or HPV-independent ⁵. The problem is
46 further stressed by the occasional overlap between the premalignant lesions, as
47 in a small percentage of cases the precursors of HPV-independent VSCC may
48 closely simulate HSIL/uVIN ^{7,8}. A recent meta-analysis has estimated that the
49 pooled prevalence of HPV-related dVIN-like lesions is about 2% ⁹. However, no
50 study has specifically addressed the description of these dVIN-like
51 intraepithelial lesions in HPV-associated VSCC.

52 In this study, we aimed to evaluate adjacent intraepithelial lesions in a
53 large series of 326 VSCC positive for DNA HPV, focusing on unusual
54 histological patterns such as intraepithelial lesions resembling dVIN and/or LS,
55 the skin lesions typically related to HPV-independent VSCC. We analyzed their
56 correlation with the HPV DNA genotype, p16 immunohistochemistry, and HPV
57 mRNA.

58 **MATERIAL AND METHODS**

59 **Case selection**

60 We reviewed a series of 1709 invasive VSCCs included in the VVAP study
61 (International Survey on HPV prevalence and type distribution in vulvar, vaginal,
62 anal, penile neoplasia) coordinated by the Catalan Institute of Oncology (ICO,
63 Barcelona-Spain) in collaboration with DDL Diagnostics Laboratory (Rijswijk, the
64 Netherlands)¹⁰.

65 We selected all cases fulfilling the following inclusion criteria: (1) invasive
66 squamous carcinoma identified in the block; (2) adequate material for
67 histological analysis, HPV detection and typing, and p16 immunohistochemical
68 staining; (3) a positive result for HPV detection by polymerase chain reaction
69 (PCR); and (4) the presence at least 1 cm of skin adjacent to the invasive
70 tumor. The study was approved by the local and ICO Ethics Committees. Three
71 hundred twenty-six cases fulfilled the inclusion criteria.

72 **Tissue preparation, nucleic-acid isolation and HPV DNA detection**

73 DNA extraction was performed on whole sections of formalin-fixed
74 paraffin-embedded (FFPE) tissue from surgical specimens or vulvar biopsies as

75 previously described ^{5,10}. Sectioning and sample preparation were carried out
76 with the highest safety measures to avoid cross-contamination. Processing and
77 pathology diagnosis were done by the ICO laboratory.

78 HPV DNA detection was performed using SPF10 PCR, DEIA and the
79 LiPA25 system (version 1, Laboratory Biomedical Products, Rijswijk, The
80 Netherlands) as previously described ^{5,10}. Each run contained negative and
81 positive controls to monitor the efficiency of DNA isolation, PCR amplification,
82 hybridization, and genotyping procedures.

83 **E6*I mRNA reverse transcription (RT-)PCR**

84 Extraction and HPV mRNA detection from tissue ribbons were performed
85 as previously described ^{5,11}. For each case, HPV type-specific E6*I mRNA RT-
86 PCR assays were performed for the HPV type(s) determined previously by
87 genotyping and for a cellular ubiquitin C gene as a control for tissue quality.
88 HPV E6*I mRNA assays were developed for the following HPV types: 16, 18,
89 26, 31, 33, 35, 39, 45, 51, 52, 53, 56, 58, 59, 66, 67, 68, 70, 73, and 82. A
90 second assay was performed to assess the presence of HPV16 E6*I mRNA in
91 all cases, irrespective of the HPV DNA result.

92 HPV mRNA extraction and detection was not performed in 22 cases in
93 which low-risk or undetermined HPV types were detected. Thus, HPV mRNA
94 results were available in 304 out of the 326 cases.

95 **p16 immunohistochemistry**

96 All tumors were stained with p16 monoclonal antibody using the CINtec
97 Histology Kit (clone E6H4; Roche-mtm-Laboratories, Heidelberg, Germany) ¹².

98 Only cases showing strong and diffuse block staining of the basal and
99 suprabasal layers were considered as positive (p16 upregulation) ¹³. The p16
100 staining was evaluated independently in the invasive tumor, in the intraepithelial
101 lesion/s and in the normal skin.

102 **Classification of the lesions as conclusively and non-conclusively** 103 **associated with HPV**

104 A case was classified as conclusively associated with HPV when it was
105 positive for HPV DNA in the invasive tumor and had either a positive staining for
106 p16 immunohistochemistry, was positive for HPV mRNA or both. Non-
107 conclusive association with HPV was defined as the identification of HPV DNA
108 in the invasive tumor with negative staining for p16 immunohistochemistry and a
109 negative result for HPV mRNA. Tumors in which only a low-risk or an
110 undetermined HPV type were identified were analyzed independently, as HPV
111 mRNA assays were not developed for these viruses.

112 **Histological evaluation**

113 A single histological slide of each case was available for review.
114 Histological evaluation was blind to HPV DNA and genotyping, HPV mRNA, and
115 p16 immunohistochemistry results. Invasive squamous carcinoma was
116 confirmed in all the 326 cases. The VSCC were classified into keratinizing,
117 basaloid, warty or non-keratinizing subtypes following the WHO 2014
118 classification ¹⁴.

119 The squamous epithelium adjacent to the neoplasms was carefully
120 evaluated in search of associated pathology. In order to establish the diagnosis
121 of intraepithelial lesion, the lesion had to be present at least 10 mm away from

122 the invasive carcinoma to rule out possible peripheral intraepithelial extension
123 simulating HSIL/uVIN or dVIN. The adjacent HSIL/uVIN was classified as a
124 basaloid or warty subtype. Briefly, the basaloid type HSIL/uVIN was
125 characterized by small atypical cells throughout the whole epidermis with a
126 striking architectural disarray ². Warty type HSIL/uVIN was diagnosed when the
127 epidermis had wide and deep rete ridges, clear pleomorphism and easily
128 recognizable koilocytotic-like changes suggestive of HPV infection ³. dVIN-like
129 lesion was defined by the presence of atypical keratinocytes limited to the basal
130 and parabasal layers in the context of a fully differentiated epithelium ³. LS-like
131 lesions were diagnosed in cases where homogenization of the collagen was
132 clearly evident, alongside other features described elsewhere ¹. The adjacent
133 skin was considered normal in the absence of HSIL/uVIN, dVIN-like lesions,
134 and/or LS-like changes.

135 **RESULTS**

136 The adjacent skin was normal in 121/326 VSCC (37.1%), whereas
137 205/326 (62.9%) showed at least one intraepithelial precursor lesion in the
138 adjacent skin. HSIL/uVIN (warty or basaloid type) was observed as the only
139 precursor lesion in 191 out of 326 tumors (58.6%). Unusual intraepithelial
140 lesions, i.e. dVIN- and/or LS-like lesions, were identified in the adjacent skin in
141 14 tumors (4.3%). Figure 1 shows the study algorithm. Table 1 shows the
142 associated lesions identified in the skin for each specific HPV type in the whole
143 series of 326 cases.

144 The HPV mRNA results were available in 304 out of the 326 tumors
145 included in the series. Overall, 281/304 VSCC in which all the tests (HPV DNA,

146 HPV mRNA and p16 results) were available, were considered as conclusively
147 associated with high-risk HPV. Among the VSCC conclusively associated with
148 HPV, 261 (92.9%) were positive for both p16 and HPV mRNA, 11 (3.9%) were
149 positive only for p16, and 9 (3.2%) were positive only for HPV mRNA. Twenty-
150 four tumors were considered as non-conclusively associated with HPV due to
151 negative p16 and HPV mRNA results. One hundred and eighty-seven of the 281
152 (66.5%) tumors conclusively associated with HPV showed HSIL/uVIN in the
153 adjacent skin, whereas only 3/24 (12.5%) of the tumors with a non-conclusive
154 association had adjacent HSIL/uVIN lesions ($p < 0.001$). The skin precursor was
155 also positive for p16 in all the p16 positive tumors showing HSIL/uVIN.

156 Among the 21 tumors with a low-risk or undetermined HPV type
157 identified, one with a low-risk HPV (HPV44) had adjacent HSIL/uVIN, with both
158 the invasive tumor and the HSIL/uVIN being negative for p16. Two tumors with
159 an HPV of undetermined type showed adjacent HSIL/uVIN and were positive for
160 p16.

161 **Unusual intraepithelial lesions**

162 Fourteen samples showed unusual intraepithelial lesion adjacent to the
163 DNA HPV-positive VSCC. Seven cases (7/326; 2.1%) showed dVIN-like
164 features, 5 cases (1.5%) showed adjacent LS-like lesions, and in 2 cases
165 (0.6%) dVIN- and LS-like lesions were identified simultaneously. Finally, in one
166 case (0.3%) LS-like features were identified in combination with typical
167 HSIL/uVIN. Table 2 shows the age, the results of the p16 immunohistochemistry
168 study of the tumor and the precursor lesion and HPV mRNA, the other

169 associated skin lesions and the histological sub-typing of the invasive tumor of
170 all the cases with dVIN-like, LS-like or both lesions.

171 Six cases were conclusively associated with HPV (3 dVIN-like lesions, 2
172 LS-like lesions, 1 with combined dVIN/LS-like lesions). All were associated with
173 HPV16 and were positive for both p16 and HPV mRNA. In all cases, the p16
174 was also positive in the adjacent dVIN-like lesion. Similarly, in the three cases
175 with LS-like lesions, the skin overlying the LS-like area showed block positivity
176 for p16, at least focally.

177 Another group of eight cases consisted of tumors with non-conclusive
178 association with HPV and tumors caused by low-risk or undetermined HPV. All
179 were positive for HPV DNA but were negative for p16 both in the tumor and in
180 the precursor lesions. In all these cases, the HPV mRNA was either negative or
181 not tested.

182 **dVIN-like and LS-like lesions in tumors conclusively associated with HPV**

183 In all dVIN-like cases identified in tumors conclusively associated with
184 HPV, atypical keratinocytes were identified in a fully differentiated epithelium,
185 with atypia strictly limited to the basal and parabasal layers, and with cells
186 having abundant eosinophilic cytoplasm (Figure 2 A and 2B). The epithelium
187 was atrophic or acanthotic with superficial parakeratosis. The rete ridges were
188 elongated and branched. The keratinocytes in the epidermis were enlarged, had
189 prominent desmosomes, abundant eosinophilic cytoplasm, large vesicular
190 nuclei and macronucleoli. No extension to skin appendages was identified.
191 None of these cases had the typical whole epithelial thickness architectural
192 disarray, prominent cytologic atypia and nuclear pleomorphism typical of

193 HSIL/uVIN. A moderate lymphocytic infiltrate was present in the papillary
194 dermis. In all cases, p16 showed diffuse block staining in the dVIN-like lesion
195 with nuclear and cytoplasmic positivity involving at least the basal and
196 suprabasal layers (Figure 2A' and 2B').

197 LS-like changes were characterized by broad condensation and
198 hyalinization of the dermal collagen in the papillary dermis (Figure 3 A). The
199 epidermis showed slight to moderate hyperkeratosis. In contrast with typical LS
200 lesions the rete ridges appeared elongated. In the two cases, p16 showed
201 diffuse block staining in the epithelium overlying the hyalinized dermal collagen
202 (Figure 3A'). A case showed combined LS-like (hyalinization of the dermal
203 collagen in the papillary dermis) and dVIN-like lesions (atypia limited to the
204 basal and parabasal layers in a fully differentiated epithelium with elongated
205 rete ridges) (Figure 3B). The epithelium showed block positivity for p16.

206 **DISCUSSION**

207 In this study, we confirm that a subset of VSCC conclusively associated
208 with HPV arises on intraepithelial lesions that have dVIN-like morphological
209 features. In a subset of these cases, the association with HPV was conclusively
210 established by positive HPV DNA result as well as the detection of HPV mRNA
211 and a positive p16 result. Interestingly, in all these lesions p16
212 immunohistochemistry showed "block positivity", both in the invasive tumor and
213 in the intraepithelial lesion, a characteristic finding in HSIL/uVIN lesions. These
214 findings indicate that HSIL/uVIN could have a wider morphological spectrum
215 than traditionally accepted, with some lesions having a dVIN-like morphology.
216 The proportion of these cases was very low, as this morphology was identified
217 in only four out of 281 tumors conclusively associated with HPV (1.4%).

218 However, this distinction may be clinically relevant as vulvar HSIL/uVIN has a
219 low progression potential and may regress spontaneously ¹⁵⁻¹⁷, whereas dVIN
220 has shown a high potential for malignant transformation ^{8,18}. Moreover, the
221 identification of dVIN-like areas at the periphery in a VSCC may be considered
222 as indirect evidence of an HPV-independent vulvar cancer ¹⁹. Interestingly, most
223 of the women with VCSS conclusively associated with HPV with dVIN-like
224 lesions were relatively old, a clinical characteristic typical of HPV-independent
225 lesions.

226 This unusual pattern of HSIL/uVIN has not specifically been described
227 previously. Nevertheless, a thorough review of the literature identified two
228 possible additional cases. Yang et al ²⁰ analyzed 12 cases of dVIN by PCR
229 and/or ISH for various HPV types, and identified one case positive for HPV type
230 31/35/51 by *in situ* hybridization. The lesion was negative for p53
231 immunohistochemistry and the patient had multifocal intraepithelial lesions,
232 some of which showed histological features overlapping with HSIL/uVIN.
233 Similarly, Haefner et al. identified HPV in 1 out of 7 cases of dVIN tested by
234 PCR and *in situ* hybridization ²¹. Finally, a recent meta-analysis has estimated
235 that the pooled prevalence of HPV-related dVIN-like lesions is about 2% ⁹.

236 The existence of HSIL/uVIN lesions with dVIN-like histological features is
237 not surprising, because morphology studies have shown clear limitations in
238 classifying vulvar tumors as HPV-associated or -independent ³⁻⁶. Additionally,
239 we have previously described that a small percentage of HPV-independent
240 VSCC have adjacent intraepithelial lesions with histological features mimicking
241 basaloid type HSIL/uVIN ^{4,7}. Finally, a number of studies have reported
242 occasional lesions with overlapping morphological features of HSIL/uVIN and

243 dVIN; although most include either HPV-independent tumors or HPV detection
244 was not made or was not reliable ^{8,20,22}.

245 In our study we found a strong correlation between the presence of high-
246 risk viral type and adjacent HSIL/uVIN, which was present in 66.8% of the
247 tumors. These results are in keeping with previous studies describing a strong
248 association between high-risk viral type HSIL/uVIN and VSCC ^{4,19,23}. The
249 percentage of HSIL/uVIN was similar for all tumors conclusively associated with
250 HPV independently of the high-risk HPV type (and also with multiple infections)
251 and ranged between 40-70%. In contrast, the percentage of HSIL/uVIN in
252 tumors in which low-risk or undetermined HPV were detected was very low.

253 The low percentage of tumors non-conclusively associated with HPV
254 (positive for HPV DNA, but negative for both p16 and HPV mRNA) that were
255 associated with HSIL/uVIN was of note in our study. These findings suggest that
256 many of these cases represent false positives for HPV DNA and are in keeping
257 with the previously proposed criteria that HPV DNA alone should not be
258 considered as sufficient evidence of HPV-association, unless a second marker
259 (p16 or HPV mRNA) is also detected ^{5,10}. The almost constant positivity for p16
260 both in the invasive tumor and the intraepithelial lesion indicates that this
261 marker can confidently be used as an HPV surrogate ^{4,5,10}.

262 The presence of LS-like changes in 3 tumors conclusively associated with
263 HPV (2 cases with LS-like lesions and 1 with coincident dVIN/LS-like lesions) is
264 striking. Although this coincidence could be largely circumstantial, and a
265 woman with LS can be infected with HPV and also develop HSIL/uVIN, and
266 subsequently, basaloid or warty VSCC, the block positivity for p16 in the skin
267 overlying the LS-like lesions in all 3 tumors, even in skin with no atypical

268 features, raises the question of the presence of LS features in some HPV-
269 associated intraepithelial lesions or the possible implication of HPV in the
270 development of LS. A few studies have reported the presence of HPV in the
271 epithelium with LS changes ²⁴ in HPV-associated VSCC, and it seems that
272 these cases have fewer mutations than conventional HPV-negative LS ²⁵.

273 The pathogenesis of the VSCC in which low risk (HPV44) or undetermined
274 HPV was detected type is uncertain. Although HPV44 is infrequent and
275 considered to be of a low-risk viral type, it has occasionally been linked to the
276 development of anogenital carcinomas through different mechanisms, without
277 p16 overexpression ²⁶. However, the role of this HPV type is not well
278 understood. To date, only one case of vulvar carcinoma of warty/basaloid
279 morphology, in which HPV44 was detected, has been reported ²⁶.

280 The main limitation of the present series is that HPV DNA or mRNA was
281 only analyzed in the whole paraffin block containing both the precursor and the
282 invasive tumor. Consequently, the possibility of a dVIN lesion, not related to the
283 tumor, growing in the vicinity of a VSCC conclusively associated with HPV
284 cannot be completely ruled out. However, the diffuse “block staining” for p16
285 identified in the dVIN-like lesions indicates that this hypothesis is rather unlikely.
286 A second limitation is that we did not study p53, which is frequently positive in
287 dVIN ²⁰. Nevertheless, in most of our cases a clear association with HPV16 was
288 demonstrated and the dVIN-like lesions showed clear staining for p16, an
289 unusual feature in HPV-negative dVIN ²⁷.

290 In conclusion, in this large series of HPV-positive VSCCs with adjacent
291 skin we found that a small proportion of tumors conclusively associated with
292 HPV may arise in intraepithelial lesions that closely simulate dVIN and LS, the

293 intraepithelial precursors of HPV-independent VSCC. Awareness of this unusual
294 feature may help to correctly classify these lesions as HPV-associated. In
295 addition, p16 staining is an excellent surrogate marker of HPV infection ²⁸ and
296 may help to identify these infrequent lesions.

297

298

299

300 **FIGURE LEGENDS**

301 **Figure 1.** Study algorithm

302

303 **Figure 2.** Differentiated vulvar intraepithelial neoplasia-like (dVIN-like) changes
304 in two cases conclusively associated with human papillomavirus (HPV) type 16.
305 Atypical keratinocytes are identified in a fully differentiated epithelium, with
306 atypia limited to the basal and parabasal layers. The rete ridges are elongated
307 and branched. The keratinocytes in the epidermis have abundant eosinophilic
308 cytoplasm, and vesicular nuclei with macronucleoli. The whole epithelial
309 thickness architectural disarray, prominent cytologic atypia and nuclear
310 pleomorphism typical of high-grade squamous intraepithelial lesion (HSIL/uVIN)
311 are absent. p16 immunohistochemistry shows block positive staining (A, A' case
312 number 1; B and B' case number 3) (A and B, hematoxylin and eosin stain; A'
313 and B' p16 immunohistochemical stain).

314

315 **Figure 3. (A)** Lichen sclerosis (LS)-like features in case number 5. There is
316 clear condensation and hyalinization of the dermal collagen in the papillary
317 dermis and subjacent inflammatory infiltrate. No atypical keratinocytes are
318 identified. p16 shows block staining involving the whole thickness of the
319 epithelium. Human papillomavirus (HPV) type 16 was identified (A').

320 **(B)** Case number 4 showing combined dVIN/LS-like lesions (case positive for
321 HPV16). Hyalinization of the dermal collagen in the papillary dermis with
322 subjacent inflammatory infiltrate coexists with elongation of the rete ridges and
323 slight atypia of the basal layer. p16 immunohistochemistry shows block positive
324 staining (B')

325 **REFERENCES**

- 326 1. Hoang LN, Park KJ, Soslow RA, et al. Squamous precursor lesions of the
327 vulva: current classification and diagnostic challenges. *Pathology*
328 2016;48:291–302.
- 329 2. del Pino M, Rodriguez-Carunchio L, Ordi J. Pathways of vulvar
330 intraepithelial neoplasia and squamous cell carcinoma. *Histopathology*
331 2013;62:161–75.
- 332 3. Rakislova N, Saco A, Sierra A, et al. Role of Human Papillomavirus in
333 Vulvar Cancer. *Adv. Anat. Pathol.* 2017;24:201–214.
- 334 4. Santos M, Landolfi S, Olivella A, et al. p16 overexpression identifies HPV-
335 positive vulvar squamous cell carcinomas. *Am. J. Surg. Pathol.*
336 2006;30:1347–56.
- 337 5. Rakislova N, Clavero O, Alemany L, et al. Histological characteristics of
338 HPV-associated and -independent squamous cell carcinomas of the
339 vulva: a study of 1594 cases. *Int. J. Cancer*, 2017;141:2517-2527
- 340 6. Dong F, Kojiro S, Borger DR, et al. Squamous Cell Carcinoma of the
341 Vulva: A Subclassification of 97 Cases by Clinicopathologic,
342 Immunohistochemical, and Molecular Features (p16, p53, and EGFR).
343 *Am. J. Surg. Pathol.* 2015; 39, 1045–53.
- 344 7. Ordi J, Alejo M, Fusté V, et al. HPV-negative vulvar intraepithelial
345 neoplasia (VIN) with basaloid histologic pattern: an unrecognized variant
346 of simplex (differentiated) VIN. *Am. J. Surg. Pathol.* 2009; 33, 1659–65.
- 347 8. Bigby SM , Eva LJ, Fong KL, et al. The Natural History of Vulvar
348 Intraepithelial Neoplasia, Differentiated Type. *Int. J. Gynecol. Pathol.*

- 349 2016; 35, 574-584.
- 350 9. Faber MT, Sand FL, Albieri V, et al. Prevalence and type distribution of
351 human papillomavirus in squamous cell carcinoma and intraepithelial
352 neoplasia of the vulva. *Int J Cancer*. 2017;1161-1169.
- 353 10. de Sanjosé S, Alemany L, Ordi J, et al. Worldwide human papillomavirus
354 genotype attribution in over 2000 cases of intraepithelial and invasive
355 lesions of the vulva. *Eur. J. Cancer* 2013; 49, 3450–61.
- 356 11. Halec G, Schmitt M, Dondog B, et al. Biological activity of
357 probable/possible high-risk human papillomavirus types in cervical
358 cancer. *Int. J. Cancer* 2013;132, 63–71.
- 359 12. Del Pino M, Garcia S, Fusté V, et al. Value of p16(INK4a) as a marker of
360 progression/regression in cervical intraepithelial neoplasia grade 1. *Am. J.*
361 *Obstet. Gynecol.* 2009; 201, 488e1-e7
- 362 13. Halec G, Alemany L, Quiros B, et al. Biological relevance of human
363 papillomaviruses in vulvar cancer. *Mod. Pathol.* 2017; 30, 549–562.
- 364 14. Crum CP. Tumours of the vulva. In: Kurman RJ, Carcangiu ML,
365 Herrington CS, Young RH, eds. *WHO Classification of Tumours of Female*
366 *Reproductive Organs*. Lyon, PA: International Agency for Research on
367 Cancer (IARC), 2014: 229–253.
- 368 15. Preti M, Igidbashian S, Costa S, et al. VIN usual type-from the past to the
369 future. *Ecancermedicalscience*. Available from:
370 <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4431399/>. Accessed
371 December 17, 2017
- 372 16. de Witte CJ, van de Sande AJ, van Beekhuizen HJ, et al. Imiquimod in

- 373 cervical, vaginal and vulvar intraepithelial neoplasia: A review. *Gynecol.*
374 *Oncol.* 2015; 139, 377–384.
- 375 17. Wright VC, Chapman W. Intraepithelial neoplasia of the lower female
376 genital tract: etiology, investigation, and management. *Semin. Surg.*
377 *Oncol.* 1992; 8, 180–90.
- 378 18. Eva LJ, Ganesan R, Chan KK, et al. Differentiated-Type Vulval
379 Intraepithelial Neoplasia Has a High-Risk Association With Vulval
380 Squamous Cell Carcinoma. *Int. J. Gynecol. Cancer* 2009; **19**, 741–744.
- 381 19. van de Nieuwenhof HP, van Kempen LC, de Hullu JA, et al. The etiologic
382 role of HPV in vulvar squamous cell carcinoma fine tuned. *Cancer*
383 *Epidemiol. Biomarkers Prev.* 2009; 18, 2061–2067.
- 384 20. Yang B, Hart WR. Vulvar intraepithelial neoplasia of the simplex
385 (differentiated) type: a clinicopathologic study including analysis of HPV
386 and p53 expression. *Am J Surg Pathol* 2000;24, 429–41.
- 387 21. Haefner HK, Tate JE, McLachlin C et al. Vulvar intraepithelial neoplasia:
388 age, morphological phenotype, papillomavirus DNA, and coexisting
389 invasive carcinoma. *Hum. Pathol.* 1995;26, 147–54.
- 390 22. Bloss JD, Liao SY, Wilczynski SP et al. Clinical and histologic features of
391 vulvar carcinomas analyzed for human papillomavirus status: evidence
392 that squamous cell carcinoma of the vulva has more than one etiology.
393 *Hum. Pathol.* 1991; 22, 711–8.
- 394 23. van der Avoort IA , Shirango H, Hoevenaars BM et al. Vulvar squamous
395 cell carcinoma is a multifactorial disease following two separate and
396 independent pathways. *Int. J. Gynecol. Pathol.* 2006; 25, 22–9.

- 397 24. Kagie MJ, Kenter GG, Zomerdijk-Nooijen Y, et al. Human papillomavirus
398 infection in squamous cell carcinoma of the vulva, in various synchronous
399 epithelial changes and in normal vulvar skin. *Gynecol. Oncol.* 1997; 67,
400 178–83.
- 401 25. Trietsch MD, Nooij LS, Gaarenstroom KN, et al. Genetic and epigenetic
402 changes in vulvar squamous cell carcinoma and its precursor lesions: a
403 review of the current literature. *Gynecol. Oncol.* 2015;136,143–57.
- 404 26. Guimerà N, Lloveras B, Lindeman J, et al. The Occasional Role of Low-
405 risk Human Papillomaviruses 6, 11, 42, 44, and 70 in Anogenital
406 Carcinoma Defined by Laser Capture Microdissection/PCR Methodology.
407 *Am. J. Surg. Pathol.* 2013; 37,1299–1310.
- 408 27. Hoevenaars BM, van der Avoort IA, de Wilde PC, et al. A panel of p16
409 INK4A , MIB1 and p53 proteins can distinguish between the 2 pathways
410 leading to vulvar squamous cell carcinoma. *Int. J. Cancer* 2008; 123,
411 2767–2773.
- 412 28. Cheng AS, Karnezis AN, Jordanet S, et al. p16 Immunostaining Allows for
413 Accurate Subclassification of Vulvar Squamous Cell Carcinoma Into HPV-
414 Associated and HPV-Independent Cases. *Int. J. Gynecol. Pathol.* 2016;
415 35, 385–393.

416